ArticleCureus2025
Differentiating Neoplastic From Non-neoplastic Gallbladder Lesions Using MUC1 and MUC5AC: An Immunohistochemical Analysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGallbladder lesions range from benign inflammatory conditions to malignancies, often progressing through pre-neoplastic stages. Accurate histopathological differentiation, particularly in early stages, remains challenging. Mucin proteins MUC1 and MUC5AC have emerged as potential immunohistochemical (IHC) markers for distinguishing neoplastic from non-neoplastic gallbladder pathology. MATERIAL AND
methodsA cross-sectional study was conducted on 52 formalin-fixed, paraffin-embedded (FFPE) gallbladder specimens from cholecystectomy cases over two years. Routine histopathological evaluation was followed by IHC staining using monoclonal antibodies against MUC1 and MUC5AC. Expression levels were semi-quantitatively scored (0-3) and statistically analyzed in relation to neoplastic status.
resultsOf the 52 cases, 29 (55.8%) were non-neoplastic and 23 (44.2%) were neoplastic, with 91.3% (n = 21) of the latter being malignant. MUC1 expression was significantly higher in neoplastic lesions (p < 0.001), with 73.9% (n = 17) showing strong (score 3) positivity. Conversely, MUC5AC was predominantly expressed in non-neoplastic lesions, with strong expression observed in 55.2% (n = 16) versus 13.0% (n = 3) of neoplastic cases (p < 0.001). MUC1 demonstrated high diagnostic performance for neoplasia (sensitivity 95.7%, specificity 75.9%), while MUC5AC showed moderate performance (sensitivity 69.6%, specificity 72.4%). The inverse expression profiles of these markers effectively differentiated malignant from benign lesions.
conclusionMUC1 and MUC5AC exhibit distinct IHC expression patterns in gallbladder pathology. MUC1 is a sensitive marker for neoplastic transformation, whereas MUC5AC is more indicative of benign or early-stage lesions. Their combined application may improve diagnostic accuracy in histologically ambiguous cases. Incorporating these biomarkers into routine pathology practice may aid early detection and better clinical decision-making. Further large-scale studies are needed to validate their prognostic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.